Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren<sup>*</sup>

Joseph, K.; Stapp, J.; Reinecke, J.; Höffken, H.; Benning, Rainer; Neuhaus, Christopher; Trautmann, M. E.; Schwerk, W. B.; Arnold, R.

doi:10.1055/s-2008-1062406

Cited by 20 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, Pauwels et al [48] described the localization of 23 out of 26 gastro-entero-pancreatic (GEP) tumours and Van Dongen et al [49] reported positive scans in four of four patients with carcinoids, one of one with MTC and one of one with an unclassified APUDoma using this technique. Ivancevic et al [50] reported a sensitivity of 67%-83% in GEP tumours and carcinoids, while Joseph et al [51], in a study of 38 patients, reported positive scans in 10 of 11 patients with gastrinomas, 10 of 11 patients with carcinoids, one of two patients with insulinomas and 10 of 14 patients with unclassified neuroendocrine tumours. The last two authors both mention the localization of tumour sites undetected with other imaging techniques.…”

Section: Comparison With Results Of Other Investigatorsmentioning

confidence: 99%

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

et al. 1993

View full text Add to dashboard Cite

Various tumours, classically specified as either neuroendocrine or non-neuroendocrine, contain high numbers of somatostatin receptors, which enable in vivo localization of the primary tumour and its metastases by scintigraphy with the radiolabelled somatostatin analogue octreotide. In addition granulomas and autoimmune processes can be visualized because of local accumulation of somatostatin receptor-positive activated mononuclear leucocytes. In many instances a positive scintigram predicts a favourable response to treatment with octreotide. It is tempting to speculate that octreotide labelled with an appropriate radionuclide might be used in cancer therapy. The successful application of radiolabelled octreotide in scintigraphy indicates the possible usefulness of other radiolabelled peptides, either native peptides or derivatives of these, in, for example, nuclear oncology. The small size of these peptides, e.g. bombesin and substance P, is of the utmost importance for a relatively fast blood clearance, thus leading to low background radioactivity. In this way peptides are powerful alternatives to (fragments of) monoclonal antibodies, the application of which to scintigraphic localization of specific cell surface antigen-bearing tumours is plagued by slow blood clearance and, hence, high background levels.

show abstract

Section: Comparison With Results Of Other Investigatorsmentioning

confidence: 99%

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

et al. 1993

View full text Add to dashboard Cite

show abstract

“…3) [11]. The failure to localize insulinomas in a substantial number of patients has also been reported by others [9,[12][13][14]19] and may be due to the absence of somatostatin receptors or the presence of a somatostatin receptor that does not bind octreotide [20]. From a cost-effectiveness analysis [4] we conclude that the highest yield in tumor detection against the lowest cost is obtained if CT scanning is applied first in all patients.…”

Section: Endocrine Pancreatic Tumorsmentioning

confidence: 58%

“…Previously unrecognized sites were found in 5 of 12 patients (42 %). Others reported comparable results [12][13][14][15][16]. Endoscopic US has been reported to have a high detection rate for gastrinomas [17].…”

Section: Endocrine Pancreatic Tumorsmentioning

confidence: 69%

Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview

Kwekkeboom

Krenning

1997

Eur Radiol

View full text Add to dashboard Cite

[111In-DTPA-D-Phe1]-octreotide is a new radiopharmaceutical with a great potential for the visualization of somatostatin receptor-positive tumors, granulomas, and diseases in which activated leukocytes play a role. The overall sensitivity of [111In-DTPA-D-Phe1]-octreotide scintigraphy to localize neuroendocrine tumors is high. In several neuroendocrine tumor types, inclusion of somatostatin receptor imaging in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life. In our opinion, this holds true for patients with carcinoids, gastrinomas, paragangliomas, small-cell lung carcinoma, and selected cases of patients with insulinomas. The value of [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with other tumors, such as breast cancer, malignant lymphomas, or in patients with granulomatous diseases, has to be established.

show abstract

“…Sie sind daher in der Regel klein, d. h. kleiner als 1,5 cm. Eine ä hnlich hohe Sensitivitä t hat offensichtlich auch die Somatostatinrezeptorszintigraphie bei allen endokrin aktiven Tumoren mit Ausnahme des Insulinoms [16,46]. Die Primä rdiagnostik stü tzt sich daher zunä chst auf Hormonbestimmungen im Basalzustand oder nach spezifischer Stimulation.…”

Section: Neuroendokrine Tumore Des Pankreasunclassified

Chirurgische Relevanz bildgebender Diagnostik bei abdominellen Tumoren – Entscheidungswege beim Pankreas

Hopt¹,

Heydasch²

1997

Chirurg

View full text Add to dashboard Cite

Imaging of tumors of the pancreas may have a series of significant implications for surgical decision making. First of all verification and localization of a suspected tumor is crucial. Later on, accurate staging of local tumor extent and of distant metastases is necessary for evaluating the indications for surgical intervention. If histologic proof of malignancy of a pancreatic lesion is needed, different imaging techniques can be used for percutaneous biopsy of the tumor. Finally imaging is required in patients with a pancreatic tumor if an obstruction of the common bile duct is treated with palliative intent by endoscopy or transhepatic intervention. A rational and efficient selection from all the imaging techniques currently available requires a clear-cut definition of what is needed for surgical decision making in each individual case. Thereby one has to take into account whether the tumor arises from the exocrine or from the endocrine tissue of the pancreas.

show abstract

Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren^*

Cited by 20 publications

References 0 publications

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview

Chirurgische Relevanz bildgebender Diagnostik bei abdominellen Tumoren – Entscheidungswege beim Pankreas

Contact Info

Product

Resources

About

Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren*

Cited by 20 publications

References 0 publications

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview

Chirurgische Relevanz bildgebender Diagnostik bei abdominellen Tumoren – Entscheidungswege beim Pankreas

Contact Info

Product

Resources

About

Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren^*